Improving quality of life in patients with metastatic prostate cancer following one cycle of 177Lu-PSMA-617 radioligand therapy: a pilot study - DocWire News

-

Introduction: To evaluate the clinical therapeutic response of PSMA targeted radioligand therapy with 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer. The current study analyzed disease-related quality of life (QoL) in patients undergoing PSMA therapy with a special focus on the association with simultaneous PSA response.

Methods: Thirty patients (age range 50-87 years, median 73.5 years) undergoing 177Lu-PSMA-617 therapy from 2014 to 2016 at our institution were included in this pilot study. Health-related QoL was assessed by EORTC QLQ-C30 questionnaire filled in at baseline and two months after initializing the PSMA-therapy. The treatment response was evaluated under three categories with regard to changes in (a) global health status and other functional scales, (b) disease-related symptoms, and (c) effects of PSA values.

Results: Most patients underwent three treatment cycles (n = 12); at least 2 cycles (n = 6) or at most 8 cycles (n = 1) were performed. Out of 30 cases, PSA response after the first cycle was observed in 73 % (n = 22). Compared to baseline, QoL was significantly improved at 2-month follow-up revealing increase in global health status (p = 0.025), role functioning (p = 0.017) and emotional functioning (0.010), and decrease in pain (p = 0.033). Global health status variation can be explained up to 20.5 % by response in PSA (p = 0.012), this improved with PSA reduction.

Conclusion: PSMA radioligand therapy seems to be an effective treatment option of metastatic castration-resistant prostate cancer patients as it improves their QoL in terms of increasing global health and mitigation of disease-related pain.



Comments

Post a Comment

Popular posts from this blog

I Wish I Didn't Need an Oncologist at All, But I'm Thankful for the One ...

-
Image
efudex side effects :: Article Creator Inmates Given Ivermectin In Jail Will Each Get $2,000 After Settlement Your browser is not supporteddetroitnews.Com detroitnews.Com wants to ensure the best experience for all of our readers, so we built our site to take advantage of the latest technology, making it faster and easier to use. Unfortunately, your browser is not supported. Please download one of these browsers for the best experience on detroitnews.Com Efudex Cream Efudex Cream Generic Name & Formulations General Description Fluorouracil 5%. Pharmacological Class Antimetabolite. How Supplied Soln (w. Drop dispenser)—10mL, 25mL; Crm—40g Efudex Cream Indications Indications Multiple actinic or solar keratoses. Superficial basal cell carcinoma when conventional therapy is impractical (5% only); see full labeling. Efudex Cream Dosage and Administration Adult Keratoses: Apply twice daily until eros
Read more

Early symptoms of cancer in males: Common warning signs

-
Image
fluciclovine f 18 :: Article Creator The U.S. Navy Might Be Done With The F/A-18 Super Hornet Fighter Will The U.S. Navy Receive Its Final F/A-18 Super Hornets? - Around the holidays, money can be tight, a fact that the United States Navy has also learned as its negotiations to buy the last batch of Super Hornets are reportedly stalled over the growing price tag. USNI News reported on Tuesday that the contract for the U.S. Navy to purchase the final twenty F/A-18 E/F Super Hornets from aerospace giant Boeing appears to be at a standstill. The Navy continues to work with Boeing on the contract for the 20 congressionally added Super Hornet aircraft. Ongoing contract negotiations cannot be discussed at this time," Capt. Michael Burks, the program manager for the F/A-18 and EA-18G office at Naval Air Systems Command, told USNI News in a statement. Previous estimates put the unit cost of the final batch of aircraft at $55.7 million, and la
Read more

20 Famous Men Who Have Had Prostate Cancer

-
Image
leukemia treatment options :: Article Creator Current And Breakthrough Treatments For Chronic Lymphocytic Leukemia (CLL) Chronic lymphocytic leukemia (CLL) is a slow-growing cancer of the immune system. Because it's slow-growing, many people with CLL won't need to start treatment for many years after their diagnosis. Once the cancer begins to grow, there are many available treatment options that can help people achieve remission. This means people can experience long periods of time when there's no sign of cancer in their bodies. The exact treatment option that you'll receive depends on a variety of factors. This includes: whether your CLL is symptomatic the stage of the CLL, based on results of blood tests and a physical exam your age your overall health While there's no cure for CLL yet, breakthroughs in the field are on the horizon. Doctors typically stage CLL using a system called the Rai system. Low
Read more